Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTR² Pilot Trial in Primary Central Nervous System Lymphoma
2022-502790-42-00Phase 2Authorised
- Sponsor
- University of Cologne
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab, rituximab, lenalidomide and methotrexate in primary central nervous system lymphoma (PCNSL), sponsored by University of Cologne. Primary endpoint: Complete response rate after at least 2 cycles of MTR². Planned start Nov 2023; status: authorised.
02
Drugs
tafasitamabrituximablenalidomidemethotrexate
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2022-502790-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502790-42-00.